Previous preclinical studies have reported that overexpression of lymphocyte activation gene-3 (LAG-3) as the coinhibitory molecules on CD8+ T cells can regulate T-cell tolerance to tumor antigens [166]. This evidence concerns the gene LAG3 and neoplasm.